MENU

MBOT Microbot Medical Forecast, Technical & Fundamental Analysis

Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space... Show more

Industry: #Biotechnology
A.I.Advisor
Nov 12, 2026

Microbot Medical (MBOT) Stock Forecast: Tracking Commercial Adoption of the First Single-Use Endovascular Robot

Key Takeaways

  • The company's forward trajectory hinges on commercial execution of its LIBERTY Endovascular Robotic System, with a Full Market Release targeted around the Society of Interventional Radiology (SIR) conference in April 2026.
  • LIBERTY's single-use, remotely operated design eliminates the capital-equipment and service burden of traditional robotic systems, positioning it as a potentially scalable, consumable-driven model.
  • Analyst sentiment remains broadly constructive, with a consensus leaning toward "Strong Buy" and published 12-month price targets ranging from roughly $2.50 to $12.00, though recent revisions reflect a more cautious view on near-term adoption.
  • Key sensitivities include hospital system-level approval timelines, the pace of converting early interest into recurring orders, and reliance on a short commercial track record.
  • Macro forces such as hospital capital spending discipline, interest rates, and evolving reimbursement and regulatory climates will directly shape adoption of new medical-robotics technology.
  • Risks include execution on the commercial ramp, the need for ongoing working capital, and competition from established surgical-robotics incumbents.
  • For additional detail on Major News, Today's Price Move, Price Targets, and Earnings, visit our dedicated ticker pages to explore these resources further.
  • Explore Trending AI Robots to see how artificial intelligence is being applied across trading and market analysis.

Strategic Positioning and Competitive Outlook

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial-stage medical device company seeking to redefine endovascular procedures through robotics. Its flagship LIBERTY Endovascular Robotic System is the first U.S. Food and Drug Administration (FDA)-cleared, single-use, remotely operated robotic platform for peripheral endovascular procedures. The company estimates an initial U.S. addressable market of approximately 2.5 million peripheral endovascular procedures annually.

The strategic thesis centers on a differentiated economic model: because LIBERTY is disposable and single-use, it avoids the substantial capital expenditure and dedicated infrastructure historically required by multi-use surgical robots. This positioning could lower the barrier to entry for hospitals and ambulatory sites, potentially enabling broader, faster penetration than capital-intensive competitors. The company has also built a growing intellectual property portfolio, with patents granted across the U.S., China, Japan, and Israel, supporting long-term monetization in markets that accept FDA-cleared devices.

Structural risks remain. The company's commercial track record is short, and adoption depends on convincing hospital administrators and interventional radiologists to shift workflow toward a new robotic category. Competition from established robotics players and the need to demonstrate consistent clinical and economic value across diverse sites will be central to medium-term positioning.

Major Catalysts Ahead

Several developments could shape investor sentiment over the coming quarters. The planned Full Market Release of LIBERTY around the SIR conference in April 2026 is a pivotal milestone, as it transitions the company from a limited, controlled launch to broader commercial availability. Early adoption signals, such as the first hospital deployments, will be closely watched as evidence of real-world demand.

Recurring-order dynamics represent another catalyst. Because LIBERTY is a consumable, repeat purchases rather than one-time capital sales will be the key proof point for the model's scalability. Management has indicated that accumulating reorders and system-level approvals are central supports for the story.

Analyst activity has become more nuanced. While firms such as B. Riley Securities and Lucid Capital have maintained Buy ratings, both reduced their price targets, and Lucid Capital lowered its target to $3 from $4, citing near-term figures that remain modest. Citizens JMP initiated coverage with a Buy rating and a $2.50 target, while H.C. Wainwright has reiterated a higher $12 target. This dispersion reflects a market weighing long-term potential against slower-than-hoped adoption, making upcoming revenue disclosures and order commentary the most important near-term data points.

Industry and Macroeconomic Forces

The company's trajectory is tied to broader healthcare economics. Elevated interest rates and ongoing capital-spending discipline among hospitals favor capital-light, consumable-based solutions such as LIBERTY, which avoid large upfront outlays. Conversely, slower capital cycles can still delay system-level approvals and adoption decisions as institutions scrutinize budgets.

Technology adoption trends in interventional radiology remain supportive, with growing interest in robotics that reduce physician radiation exposure and improve ergonomics. Regulatory climate is also material: the company's strategy of expanding into markets that accept FDA-cleared devices could accelerate international entry, while any shifts in FDA priorities or tariff policies on imports remain watch items. Inflation and hospital staffing pressures may further favor efficiency-enhancing tools, though reimbursement clarity will ultimately influence how quickly new procedures are embraced.

Trend Prediction Engine

For traders seeking a forward-looking, data-driven view of MBOT and other instruments, Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help identify whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the next week or month. It is built to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad range of tradable instruments. The platform includes searchable prediction categories, historical context, and alert-oriented functionality to support ongoing monitoring. Consider exploring the Trend Prediction Engine to complement your own research and stay informed on evolving market signals.

2026 Outlook and Long-Term Themes to Watch

Looking toward 2026 and beyond, the dominant theme is the transition from regulatory clearance to commercial scale. Success will be measured by the pace at which early interest converts into recurring orders, and by whether the Full Market Release broadens the installed base beyond early adopters. Cost-structure evolution is another focus: a consumable model carries attractive margin potential at scale but requires sufficient procedure volume to offset operating costs and support working capital.

Market expansion opportunities exist internationally, where acceptance of FDA-cleared devices and a growing patent portfolio could open new geographies. Competitive threats from incumbent robotics firms and emerging technologies will test LIBERTY's differentiation, while regulatory developments and reimbursement decisions will shape long-term addressable demand.

Analyst consensus reflects a mix of enthusiasm and caution. The average 12-month price target across surveyed firms sits in the mid-single-digit range, with a wide spread between conservative and more aggressive estimates. This dispersion underscores that near-term execution—rather than the technology's long-term promise—will likely determine how sentiment evolves. Investors monitoring the name will watch order metrics, hospital adoption announcements, and any updates to published analyst price targets as indicators of whether commercialization is tracking expectations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Interact to see
Advertisement
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published Earnings

MBOT is expected to report earnings to rise 3.67% to -9 cents per share on March 03

Microbot Medical MBOT Stock Earnings Reports
Q4'26
Est.
$-0.09
Q3'26
Missed
by $0.01
Q2'26
Est.
$-0.08
Q1'26
Beat
by $0.03
Q4'25
Beat
by $0.02
The last earnings report on November 13 showed earnings per share of -9 cents, missing the estimate of -7 cents. With 674.26K shares outstanding, the current market capitalization sits at 74.55M.
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SNAG5.000.65
+14.94%
Leverage Shares 2x Long SNAP Daily ETF (SNAG)
TSLQ15.50-0.01
-0.06%
Tradr 2X Short TSLA Daily ETF New Oct 2025 (TSLQ)
FJUL59.58-0.50
-0.83%
FT Vest U.S. Equity Buffer ETF - July (FJUL)
UCIB35.25-0.48
-1.36%
ETRACS CMCI Total Return ETN Series B (UCIB)
IMF52.27-0.79
-1.49%
Invesco Managed Futures Strategy ETF (IMF)

MBOT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MBOT has been loosely correlated with AGPU. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if MBOT jumps, then AGPU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBOT
1D Price
Change %
MBOT100%
+6.92%
AGPU - MBOT
37%
Loosely correlated
-4.71%
BWAY - MBOT
34%
Loosely correlated
-2.98%
QSI - MBOT
33%
Loosely correlated
-4.72%
AIMD - MBOT
32%
Poorly correlated
+7.89%
CODX - MBOT
31%
Poorly correlated
-12.85%
More

Groups containing MBOT

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBOT
1D Price
Change %
MBOT100%
+6.92%
Medical/Nursing Services
industry (138 stocks)
5%
Poorly correlated
-0.39%
Health Services
industry (238 stocks)
4%
Poorly correlated
-1.42%
A.I. Advisor
published General Information

General Information

a company, which specializes in the research, design, development and commercialization of micro-robotics assisted medical technologies

Industry MedicalNursingServices

Industry
Biotechnology
Address
175 Derby Street
Phone
+1 781 875-3605
Employees
43
Web
https://www.microbotmedical.com
Microbot Medical (MBOT) Stock Forecast: Tracking Commercial Adoption of the First Single-Use Endovascular Robot